Free Trial
NASDAQ:MGX

Metagenomi (MGX) Stock Price, News & Analysis

Metagenomi logo
$1.41 +0.15 (+11.90%)
Closing price 04/4/2025 04:00 PM Eastern
Extended Trading
$1.43 +0.02 (+1.42%)
As of 04/4/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Metagenomi Stock (NASDAQ:MGX)

Key Stats

Today's Range
$1.23
$1.43
50-Day Range
$1.26
$2.85
52-Week Range
$1.23
$10.57
Volume
593,825 shs
Average Volume
754,560 shs
Market Capitalization
$52.71 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.00
Consensus Rating
Moderate Buy

Company Overview

Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.

Remove Ads

Metagenomi Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
33rd Percentile Overall Score

MGX MarketRank™: 

Metagenomi scored higher than 33% of companies evaluated by MarketBeat, and ranked 667th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Metagenomi has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Metagenomi has only been the subject of 2 research reports in the past 90 days.

  • Read more about Metagenomi's stock forecast and price target.
  • Earnings Growth

    Earnings for Metagenomi are expected to decrease in the coming year, from ($2.46) to ($2.52) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Metagenomi is -0.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Metagenomi is -0.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Metagenomi's valuation and earnings.
  • Percentage of Shares Shorted

    12.07% of the float of Metagenomi has been sold short.
  • Short Interest Ratio / Days to Cover

    Metagenomi has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Metagenomi has recently decreased by 0.38%, indicating that investor sentiment is improving.
  • Dividend Yield

    Metagenomi does not currently pay a dividend.

  • Dividend Growth

    Metagenomi does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    12.07% of the float of Metagenomi has been sold short.
  • Short Interest Ratio / Days to Cover

    Metagenomi has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Metagenomi has recently decreased by 0.38%, indicating that investor sentiment is improving.
  • News Sentiment

    Metagenomi has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Metagenomi this week, compared to 6 articles on an average week.
  • Search Interest

    Only 5 people have searched for MGX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
Receive MGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Metagenomi and its competitors with MarketBeat's FREE daily newsletter.

MGX Stock News Headlines

Metagenomi price target lowered to $7 from $14 at H.C. Wainwright
Trump to unlock 15-figure fortune for America (May 3rd) ?
We were shown this map by former Presidential Advisor, Jim Rickards, one of the most politically connected men in America. Rickards has spent his fifty-year career in the innermost circles of the U.S. government and banking. And he believes Trump could soon release this frozen asset to the public.
Chardan Capital Forecasts Metagenomi FY2025 Earnings
See More Headlines

MGX Stock Analysis - Frequently Asked Questions

Metagenomi's stock was trading at $3.61 at the beginning of the year. Since then, MGX stock has decreased by 60.9% and is now trading at $1.41.
View the best growth stocks for 2025 here
.

Metagenomi, Inc. (NASDAQ:MGX) issued its quarterly earnings results on Monday, March, 17th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by $0.01. The business earned $9.61 million during the quarter, compared to the consensus estimate of $13.18 million. Metagenomi had a negative trailing twelve-month return on equity of 43.23% and a negative net margin of 134.27%.

Metagenomi (MGX) raised $94 million in an IPO on Friday, February 9th 2024. The company issued 6,250,000 shares at a price of $15.00 per share.

Shares of MGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Metagenomi investors own include Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Home Depot (HD).

Company Calendar

Last Earnings
3/17/2025
Today
4/05/2025
Next Earnings (Estimated)
5/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:MGX
Previous Symbol
NASDAQ:MGX
Fax
N/A
Employees
236
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$13.00
High Stock Price Target
$20.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+822.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-68,250,000.00
Net Margins
-134.27%
Pretax Margin
-137.13%

Debt

Sales & Book Value

Annual Sales
$52.30 million
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$52.71 million
Optionable
N/A
Beta
-0.27
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:MGX) was last updated on 4/5/2025 by MarketBeat.com Staff
From Our Partners